Allergy Therapeutics plc (LON:AGY – Get Free Report)’s share price hit a new 52-week low during trading on Tuesday. The stock traded as low as GBX 4.50 and last traded at GBX 4.80, with a volume of 15626 shares trading hands. The stock had previously closed at GBX 4.75.
Allergy Therapeutics Stock Performance
The stock has a market cap of £303.96 million, a P/E ratio of -4.95, a PEG ratio of -30.70 and a beta of 0.83. The stock has a fifty day simple moving average of GBX 5.25 and a 200-day simple moving average of GBX 7.58. The company has a quick ratio of 1.48, a current ratio of 1.13 and a debt-to-equity ratio of 629.58.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Record French Debt Could Create Opportunities for U.S. Market Operators
- InvenTrust’s Sell-Off Opens a Potential Entry Point
- Curaleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation
- Why onsemi’s Synaptics Pivot Could Be a Game Changer
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
